| CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME | diabetic macular edema | Active, not recruiting | Phase 3 | 2026-10-02 | | NCT07449923 |
|---|
| A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) | diabetic macular edema | Active, not recruiting | Phase 3 | 2026-09-18 | | NCT06491914 |
|---|
| A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 | wet macular degeneration | Active, not recruiting | Phase 3 | 2026-09-03 | | NCT06683742 |
|---|
| A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 | wet macular degeneration | Active, not recruiting | Phase 3 | 2026-09-03 | | NCT06668064 |
|---|
| A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE | eye disorder, macular degeneration, macular retinal edema, retinal degeneration, retinal disorder | Recruiting | Phase 3 | 2026-05-18 | | NCT06996080 |
|---|
| A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK | eye disorder, macular degeneration, macular retinal edema, retinal degeneration, retinal disorder | Recruiting | Phase 3 | 2026-05-18 | | NCT06990399 |
|---|
| Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema | Diabetic Macular Edema (DME) | Active, not recruiting | Phase 2 | 2025-10-30 | | NCT06116916 |
|---|